TandemLife is now a part of LivaNova, Learn More Here.
COVID-19 UPDATES:The U.S. Food and Drug Administration (FDA) issued guidance on April 6, 2020 to temporarily expand the availability of devices used in extracorporeal membrane oxygenation (ECMO) therapy to address the novel coronavirus (COVID-19) public health emergency. As a result of the guidance, cardiopulmonary devices, including select devices from TandemLife | LivaNova, are now temporarily indicated for ECMO therapy greater than 6 hours. To read the full announcement, click here.
Pittsburgh-based medical device company CardiacAssist Inc. has changed its name to TandemLife to better reflect its future, and it has plans to nearly double the size of the company in 18 months. Privately held CardiacAssist began life 1996 and in 2001 rolled out its first product, TandemHeart, which provides people who need it with cardiac support. But
Newly formed TandemLife will offer several innovative product lines to help medical professionals improve the quality of care for patients in need of advanced cardiac and respiratory support. PITTSBURGH, Penn., March 31, 2016 (PR Newswire) — CardiacAssist, Inc. today announced a rebranding of the privately-held company and will begin to do business as TandemLife as it rolls